Back
Day Range
$114.02
$116.54
52-Week Range
$73.31
$125.14
Volume
4,771,613
50D / 200D Avg
$115.65
/
$94.64
Prev Close
$115.68
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 15.8 | 0.3 |
| P/B | 5.5 | 2.9 |
| ROE % | 36.9 | 3.7 |
| Net Margin % | 28.1 | 3.8 |
| Rev Growth 5Y % | 7.5 | 10.0 |
| D/E | 1.0 | 0.2 |
Analyst Price Target
Hold
$128.54
+10.4%
Low: $100.00
High: $150.00
Forward P/E
22.6
Forward EPS
$5.12
EPS Growth (est.)
+0.0%
Est. Revenue
67 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$10.16
$9.87 – $10.37
|
74 B | 5 |
| FY2029 |
$10.36
$10.07 – $10.58
|
75 B | 2 |
| FY2028 |
$10.77
$8.85 – $13.13
|
75 B | 7 |
Insider Trading Activity
Buy ratio (90d)
0.0%
15 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 6, 2026 |
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
|
sell | 37,685 | $120.92 | $4,557,025 |
| Feb 6, 2026 |
Oosthuizen Johannes Jacobus
President, U.S. Market
|
sell | 15,000 | $121.87 | $1,827,992 |
| Jan 26, 2026 |
Litchfield Caroline
EVP & CFO
|
grant | 15,852 | $107.40 | $1,702,505 |
| Jan 26, 2026 |
Guindo Chirfi
Chief Marketing Officer
|
grant | 9,865 | $107.40 | $1,059,501 |
| Jan 26, 2026 |
Li Dean Y
Executive VP & President, MRL
|
grant | 20,469 | $107.40 | $2,198,371 |
| Jan 26, 2026 |
Davis Robert M
Chairman, CEO & President
|
grant | 47,434 | $107.40 | $5,094,412 |
| Dec 31, 2025 |
Seidman Christine E
Director
|
grant | 77 | $105.26 | $8,105 |
| Nov 10, 2025 |
Downing Cristal N
Chief Comm. & Public Afrs Ofcr
|
sell | 7,085 | $87.00 | $616,395 |
| Sep 30, 2025 |
Coe Mary Ellen
Director
|
grant | 357 | $83.93 | $29,963 |
| Sep 30, 2025 |
Seidman Christine E
Director
|
grant | 97 | $83.93 | $8,141 |
| Jun 30, 2025 |
GLOCER THOMAS H
Director
|
grant | 616 | $79.16 | $48,763 |
| Jun 30, 2025 |
Seidman Christine E
Director
|
grant | 103 | $79.16 | $8,153 |
| May 30, 2025 |
Craig Pamela J.
Director
|
grant | 2,863 | $76.84 | $219,993 |
| May 30, 2025 |
Seidman Christine E
Director
|
grant | 2,863 | $76.84 | $219,993 |
| Mar 31, 2025 |
Seidman Christine E
Director
|
grant | 91 | $89.76 | $8,168 |
Key Takeaways
Revenue grew 7.49% annually over 5 years — modest growth
ROE of 36.91% indicates high profitability
Net margin of 28.08% shows strong profitability
Generating 12.36B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6.18%
Capital efficient — spends only 6.33% of revenue on capex
Growth
Revenue Growth (5Y)
7.49%
Revenue (1Y)1.31%
Earnings (1Y)6.64%
FCF Growth (3Y)16.27%
Quality
Return on Equity
36.91%
ROIC19.47%
Net Margin28.08%
Op. Margin41.19%
Safety
Debt / Equity
0.96
Current Ratio1.54
Interest Coverage0.00
Valuation
P/E Ratio
15.76
P/B Ratio5.47
EV/EBITDA12.09
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1.31% | Revenue Growth (3Y) | 3.99% |
| Earnings Growth (1Y) | 6.64% | Earnings Growth (3Y) | 607.18% |
| Revenue Growth (5Y) | 7.49% | Earnings Growth (5Y) | 8.75% |
| Profitability | |||
| Revenue (TTM) | 65.01B | Net Income (TTM) | 18.25B |
| ROE | 36.91% | ROA | 13.34% |
| Gross Margin | 81.50% | Operating Margin | 41.19% |
| Net Margin | 28.08% | Free Cash Flow (TTM) | 12.36B |
| ROIC | 19.47% | FCF Growth (3Y) | 16.27% |
| Safety | |||
| Debt / Equity | 0.96 | Current Ratio | 1.54 |
| Interest Coverage | 0.00 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 15.76 | P/B Ratio | 5.47 |
| P/S Ratio | 4.43 | PEG Ratio | 1.88 |
| EV/EBITDA | 12.09 | Dividend Yield | 0.03% |
| Market Cap | 287.74B | Enterprise Value | 323.71B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65.01B | 64.17B | 60.12B | 59.28B | 48.70B |
| Net Income | 18.25B | 17.12B | 365.00M | 14.52B | 13.05B |
| EPS (Diluted) | 7.28 | 6.74 | 0.14 | 5.71 | 5.14 |
| Gross Profit | 52.98B | 48.98B | 43.99B | 41.87B | 35.08B |
| Operating Income | 26.78B | 20.22B | 2.95B | 18.28B | 13.20B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 136.87B | 117.11B | 106.68B | 109.16B | 105.69B |
| Total Liabilities | 84.20B | 70.73B | 69.04B | 63.10B | 67.44B |
| Shareholders' Equity | 52.61B | 46.31B | 37.58B | 45.99B | 38.18B |
| Total Debt | 50.53B | 38.27B | 36.27B | 31.99B | 34.63B |
| Cash & Equivalents | 14.57B | 13.24B | 6.84B | 12.69B | 8.10B |
| Current Assets | 43.52B | 38.78B | 32.17B | 35.72B | 30.27B |
| Current Liabilities | 28.33B | 28.42B | 25.69B | 24.24B | 23.87B |